U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C10H15NO.H2O4S
Molecular Weight 428.543
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PSEUDOEPHEDRINE SULFATE

SMILES

OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C2=CC=CC=C2

InChI

InChIKey=CAVQBDOACNULDN-NRCOEFLKSA-N
InChI=1S/2C10H15NO.H2O4S/c2*1-8(11-2)10(12)9-6-4-3-5-7-9;1-5(2,3)4/h2*3-8,10-12H,1-2H3;(H2,1,2,3,4)/t2*8-,10+;/m00./s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12373557 | http://www.mayoclinic.org/drugs-supplements/ephedra--ma-huang/background/hrb-20059270 | https://www.sudafed.com/adult-products/congestion/sudafed-24-hour#uses-and-directions | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0011888 | https://www.ncbi.nlm.nih.gov/pubmed/11772135 | https://www.ncbi.nlm.nih.gov/pubmed/10449190 | https://www.ncbi.nlm.nih.gov/pubmed/12954796

Pseudoephedrine is a sympathomimetic drug. Pseudoephedrine acts as an adrenomimetic and inhibitor of monoamine transporters. Ephedra sinica, a species of ephedra (ma huang), contains ephedrine and pseudoephedrine. Ephedra has been found to stimulate the nervous system, increase airflow into the lungs and constrict blood vessels. In combination with caffeine, ephedra appears to cause weight loss. Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Pseudoephedrine is used to relieve nasal or sinus congestion caused by the common cold, sinusitis, and hay fever and other respiratory allergies.

CNS Activity

Originator

Ladenburg, A.
4
Sources: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889).
Curator's Comment: (+)-threo-isomer of ephedrine, q.v. Isoln from E. vulgaris: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889). Synthesis: E. Späth, R. Göhring, Monatsh. Chem. 41, 319 (1920). reference retrieved from http://www.drugfuture.com/chemdata/pseudoephedrine.html

Approval Year

1961
146
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 5.6 µM [IC50]
Inhibitor
8297
 1.18 µM [IC50]
Agonist
2678
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
SUDAFED 24 HOUR

Approved Use

temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies; reduces swelling of nasal passages; relieves sinus pressure

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
292 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4346 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.3 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Other AEs: Rhabdomyolysis, Creatine kinase increased...
Other AEs:
Rhabdomyolysis (1 patient)
Creatine kinase increased (1 patient)
Blood myoglobin increased (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Other AEs: Tension, Dry mouth...
Other AEs:
Tension (10 patients)
Dry mouth (6 patients)
Tachycardia (9 patients)
Palpitations (10 patients)
Anxiety (13 patients)
Insomnia (12 patients)
Anorexia (7 patients)
Restlessness (10 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
unhealthy, 3 years
n = 1
Health Status: unhealthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
Disc. AE: Urinary retention...
AEs leading to
discontinuation/dose reduction:
Urinary retention (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
720 mg 1 times / day multiple, oral
Highest studied dose
Dose: 720 mg, 1 times / day
Route: oral
Route: multiple
Dose: 720 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
unhealthy, 38.8 years
n = 38
Health Status: unhealthy
Age Group: 38.8 years
Sex: M+F
Population Size: 38
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
unhealthy, 87 years
n = 1
Health Status: unhealthy
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
Other AEs: Hypertension...
Other AEs:
Hypertension (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
AEs

AEs

AESignificanceDosePopulation
Blood myoglobin increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Creatine kinase increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Rhabdomyolysis 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Palpitations 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Restlessness 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Tension 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Insomnia 12 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Anxiety 13 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Dry mouth 6 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Anorexia 7 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Tachycardia 9 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Urinary retention acute, 1 patient
Disc. AE
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
unhealthy, 3 years
n = 1
Health Status: unhealthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Hypertension 1 patient
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
unhealthy, 87 years
n = 1
Health Status: unhealthy
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:51209
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51209
ZINC
ZINC000000020259
http://zinc15.docking.org/substances/ZINC000000020259
eMolecules
494893
https://www.emolecules.com/cgi-bin/more?vid=494893
PubMed

PubMed

TitleDatePubMed
Cetirizine/pseudoephedrine.
2001
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?
2001
Recurrent ischaemic colitis associated with pseudoephedrine use.
2001 Apr
Mass spectrometric quantitation of chiral drugs by the kinetic method.
2001 Apr 15
Study on the chiral recognition of the enantiomers of ephedrine derivatives with neutral and sulfated heptakis(2,3-O-diacetyl)-beta-cyclodextrins using capillary electrophoresis, UV, nuclear magnetic resonance spectroscopy and mass spectrometry.
2001 Apr 20
Stereocontrolled Mannich reaction with enolizable imines using (S,S)-(+)-pseudoephedrine as chiral auxiliary. Asymmetric synthesis of alpha,beta-disubstituted beta-aminoesters and beta-lactams.
2001 Dec 28
New observations on the secondary chemistry of world Ephedra (Ephedraceae).
2001 Jul
[Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: protocol of GOELAM Sa3].
2001 Mar-Apr
Comparative oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine.
2001 Mar-Apr
Acute psychosis due to the interaction of legal compounds--ephedra alkaloids in 'vigueur fit' tablets, caffeine in 'red bull' and alcohol.
2001 Oct
Separation and determination of ephedrine alkaloids and tetramethylpyrazine in Ephedra sinica Stapf by gas chromatography-mass spectrometry.
2001 Sep
Kinetic spectrophotometric methods for the quantitation of triprolidine in bulk and in drug formulations.
2001 Sep
Rapid chiral on-chip separation with simplified amperometric detection.
2001 Sep 14
Myocardial infarction temporally related to ephedra--a possible role for the coronary microcirculation.
2002
Pseudoephedrine causing mania-like symptoms.
2002 Feb 22
Immediate hypersensitivity due to pseudoephedrine.
2002 Jan
Modifying the bitterness of selected oral pharmaceuticals with cation and anion series of salts.
2002 Jul
Erythrodermia to pseudoephedrine in a patient with contact allergy to phenylephrine.
2002 Jul-Aug
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use.
2002 Jun
Oral medications.
2002 Mar
A moderate dose of pseudoephedrine does not alter muscle contraction strength or anaerobic power.
2002 Nov
Enhanced enantio- and diastereoselectivity via confinement and cation binding: yang photocyclization of 2-benzoyladamantane derivatives within zeolites.
2002 Nov 29
[Cutaneous complications following liver transplantation: epidemiologic and clinical study in 86 patients].
2002 Oct
Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers.
2002 Oct
Severe adverse drug reactions due to pseudoephedrine from over-the-counter medications.
2002 Sep
Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane.
2003 Apr 14
Chiral analysis of amphetamine-type stimulants using reversed-polarity capillary electrophoresis/positive ion electrospray ionization tandem mass spectrometry.
2003 Jun
In vitro evaluation of apical microleakage following canal filling with a coated carrier system compared with lateral and thermomechanical Gutta-Percha condensation techniques.
2003 May
Canine model of nasal congestion and allergic rhinitis.
2003 May
Patents

Patents

05560921
4
06835559
6
07888040
4
JP2002316927A
5
JP2002332229A
4
JP2003089638A
4
JP2007176958A
4
JP2007525670A
148
JP2008081510A
4
JP2008510795A
76
JP2010241834A
9
JP2010270109A
4
JP3553083B2
49
JPH02134A
4
JPS62221625A
4

Sample Use Guides

In Vivo Use Guide
SUDAFED® 24 HOUR TABLET, EXTENDED RELEASE; ORAL (PSEUDOEPHEDRINE HYDROCHLORIDE) 240MG adults and children 12 years and older: a tablet with water every 24 hours children under 12 years: do not use this product in children under 12 years of age
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Pseudoephedrine inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.
Unknown
Name Type Language
PSEUDOEPHEDRINE SULFATE
MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
D-PSEUDOEPHEDRINE SULFATE
Common Name English
PSEUDOEPHEDRINE SULFATE COMPONENT OF CLARINEX-D
Common Name English
PSEUDOEPHEDRINE SULFATE COMPONENT OF DRIXORAL PLUS
Common Name English
DISOBROM COMPONENT PSEUDOEPHEDRINE SULFATE
Common Name English
BROMPHERIL COMPONENT PSEUDOEPHEDRINE SULFATE
Common Name English
PSEUDOEPHEDRINE SULFATE COMPONENT OF DRIXORAL
Common Name English
PSEUDOEPHEDRINE SULFATE [MI]
Common Name English
PSEUDOEPHEDRINE SULFATE COMPONENT OF DISOPHROL
Common Name English
PSEUDOEPHEDRINE SULFATE [USP-RS]
Common Name English
RESPORAL COMPONENT PSEUDOEPHEDRINE SULFATE
Common Name English
PSEUDOEPHEDRINE SULFATE COMPONENT OF RESPORAL
Common Name English
PSEUDOEPHEDRINE SULFATE [MART.]
Common Name English
TRINALIN COMPONENT PSEUDOEPHEDRINE SULFATE
Common Name English
PSEUDOEPHEDRINE SULFATE COMPONENT OF CLARITIN-D
Common Name English
(+)-PSEUDOEPHEDRINE SULPHATE
Common Name English
DISOPHROL COMPONENT PSEUDOEPHEDRINE SULFATE
Common Name English
Pseudoephedrine sulfate [WHO-DD]
Common Name English
PSEUDOEPHEDRINE SULFATE COMPONENT OF DISOBROM
Common Name English
PSEUDOEPHEDRINE SULFATE [ORANGE BOOK]
Common Name English
CLARINEX-D COMPONENT PSEUDOEPHEDRINE SULFATE
Common Name English
CLARITIN-D COMPONENT PSEUDOEPHEDRINE SULFATE
Common Name English
SCH-4855
Code English
(+)-PSEUDOEPHEDRINE SULFATE
Common Name English
SCH 4855
Code English
PSEUDOEPHEDRINE SULFATE [USP MONOGRAPH]
Common Name English
PSEUDOEPHEDRINE SULFATE [USAN]
Common Name English
PSEUDOEPHEDRINE SULPHATE
Common Name English
DRIXORAL COMPONENT PSEUDOEPHEDRINE SULFATE
Common Name English
PSEUDOEPHEDRINE SULFATE COMPONENT OF TRINALIN
Common Name English
BENZENEMETHANOL, .ALPHA.-(1-(METHYLAMINO)ETHYL)-, (S-(R (SUP *),R (SUP *))-
Common Name English
PSEUDOEPHEDRINE SULFATE [VANDF]
Common Name English
PSEUDOEPHEDRINE SULFATE COMPONENT OF BROMPHERIL
Common Name English
DRIXORAL PLUS COMPONENT PSEUDOEPHEDRINE SULFATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29709
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
CFR 21 CFR 341.20
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
DEA NO. 8112
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
EMA ASSESSMENT REPORTS AERINAZE (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
Code System Code Type Description
PUBCHEM
9802673
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
DAILYMED
Y9DL7QPE6B
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
SMS_ID
100000093436
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
EVMPD
SUB15044MIG
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID20889379
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
RS_ITEM_NUM
1581504
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
RXCUI
91169
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
231-243-2
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
DRUG BANK
DBSALT000150
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
ChEMBL
CHEMBL1590
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
MERCK INDEX
m9294
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY Merck Index
FDA UNII
Y9DL7QPE6B
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
NCI_THESAURUS
C47696
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
CAS
7460-12-0
Created by admin on Fri Dec 15 15:09:29 GMT 2023 , Edited by admin on Fri Dec 15 15:09:29 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of PSEUDOEPHEDRINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966